ArticleJournal of the National Cancer Institute2022
A Problematic Biomarker Trial Design.
Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.JCO oncology practice · 2026Trial
- IL-23 as a potential mediator of immune evasion and therapeutic target in laryngeal squamous cell carcinoma.BMC cancer · 2026Article
- Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.Clinical trials (London, England) · 2023Article
- Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.Journal of the National Cancer Institute · 2023Article
- Design and reporting of phase III oncology trials with prospective biomarker validation.Journal of the National Cancer Institute · 2023Article
- Clinical Benefit Scales and Trial Design: Some Statistical Issues.Journal of the National Cancer Institute · 2022Review
- Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.Diagnostics (Basel, Switzerland) · 2022Review
- Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups.Pharmaceutical statisticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient biomarker-driven randomized clinical trials are a key tool for implementing precision oncology. A commonly used biomarker phase III design is focused on testing the treatment effect in biomarker-positive and overall study populations. This approach may result in recommending new treatments to biomarker-negative patients when these treatments have no benefit for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.